Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalatesBig-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and Share XDaiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalateshttps://pharmaphorum.com/news/daiichi-sankyo-takes-seattle-genetics-to-court-as-battle-over-breast-cancer-drug-escalates/
Astellas gets EU approval for AML drug XospataThe European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia Share XAstellas gets EU approval for AML drug Xospatahttps://pharmaphorum.com/news/astellas-gets-eu-approval-for-aml-drug-xospata/
AZ/Daiichi’s possible breast cancer blockbuster gets fast US reviewThe FDA has granted a priority review for AstraZeneca and Daiichi Sankyo’s potential breast cancer blockbuster trastuzumab deruxtecan, Share XAZ/Daiichi’s possible breast cancer blockbuster gets fast US reviewhttps://pharmaphorum.com/news/fda-grants-priority-review-for-trastuzumab-deruxtecan/
Astellas maintains lead over Daiichi Sankyo with CHMP okay for XospataAstellas’ FLT3 inhibitor for acute myeloid leukaemia (AML) – Xospata – has been recommended for approval in Europe, Share XAstellas maintains lead over Daiichi Sankyo with CHMP okay for Xospatahttps://pharmaphorum.com/news/astellas-maintains-lead-over-daiichi-sankyo-with-aml-drug-xospata/
Daiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourDaiichi Sankyo’s pexidartinib has become the first FDA-approved therapy for tenosynovial giant cell tumour (TGCT), a rare form Share XDaiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourhttps://pharmaphorum.com/news/daiichi-sankyos-pexidartinib-is-first-fda-approved-drug-for-rare-tumour/
Daiichi waits on FDA as AML drug quizartinib approved in JapanThe Japanese regulator has approved Daiichi Sankyo’s quizartinib for certain patients with acute myeloid leukaemia (AML), amid doubts Share XDaiichi waits on FDA as AML drug quizartinib approved in Japanhttps://pharmaphorum.com/news/daiichi-waits-on-fda-as-aml-drug-quizartinib-approved-in-japan/
Daiichi Sankyo in talks over OTC unit sale – reportsDaiichi Sankyo is in talks with several companies over a sale of its over-the-counter (OTC) business, according to Share XDaiichi Sankyo in talks over OTC unit sale – reportshttps://pharmaphorum.com/news/daiichi-sankyo-in-talks-over-otc-unit-sale-reports/
Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and moreAZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, Share XOncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and morehttps://pharmaphorum.com/views-and-analysis/oncology-round-up-az-and-daiichi-score-key-trial-win-with-breast-cancer-antibody-and-more/
FDA advisors reject one Daiichi Sankyo cancer drug, back anotherDaiichi Sankyo had a day of mixed fortunes after advisers to the US regulator voted against approval for Share XFDA advisors reject one Daiichi Sankyo cancer drug, back anotherhttps://pharmaphorum.com/news/fda-advisors-reject-one-daiichi-sankyo-cancer-drug-back-another/
